PFAS are often described as “forever chemicals” because many of them resist natural degradation and can remain in water, soil, wildlife and the human body for years. But persistence alone does not tell us exactly how exposure affects health. The more important question is this: what does the scientific evidence show about long-term exposure to PFAS?
Research has expanded rapidly over the past two decades. Studies in humans, laboratory animals and exposed communities have identified several health effects associated with certain PFAS, particularly PFOA and PFOS. The evidence is strongest for changes in cholesterol, reduced immune responses, pregnancy-related effects and kidney or testicular cancer. Other outcomes, including thyroid disease, liver effects and developmental impacts, remain active areas of research.
PFAS are a large family of thousands of substances. They are used in applications ranging from firefighting foams and industrial processes to stain-resistant textiles, food packaging and non-stick materials. Their chemical structures differ, so findings for one compound should not automatically be applied to every PFAS. Nevertheless, the widespread detection of multiple PFAS in people and the environment has made long-term exposure a significant public health concern.
How people are exposed to PFAS
For most people, exposure occurs through a combination of sources rather than a single product. Drinking water can be an important pathway, especially near airports, military sites, industrial facilities, landfills and locations where aqueous film-forming foam has been used. Food, indoor dust, consumer products and contaminated soil can also contribute.
PFAS can enter the body when contaminated water or food is swallowed. Some compounds may also be absorbed through contact with treated materials, although ingestion is generally considered the more important route for the general population. Once absorbed, long-chain PFAS such as PFOA and PFOS can remain in the body for years. Blood levels decline gradually, not immediately, after exposure is reduced.
This does not mean that every person exposed to PFAS will develop an illness. Risk depends on the chemical involved, the concentration, the duration of exposure, individual characteristics and exposure to other environmental or lifestyle factors. The scientific evidence describes population-level patterns rather than predicting what will happen to one individual.
What the evidence says about the strongest health associations
Health agencies and expert review bodies have assessed PFAS evidence using epidemiological studies, toxicology research and mechanistic data. Although methods differ between organisations, several areas of concern appear repeatedly.
- Immune system effects: Exposure to some PFAS is associated with a weaker antibody response to certain vaccinations, particularly in children.
- Cholesterol changes: Higher blood concentrations of PFOA and PFOS have been linked with increased total and low-density lipoprotein cholesterol.
- Pregnancy and development: Studies have reported associations with reduced birth weight, pregnancy-induced hypertension and pre-eclampsia for some PFAS.
- Cancer: The evidence is strongest for associations between PFOA exposure and kidney and testicular cancer.
- Liver effects: PFAS can alter liver enzymes and lipid metabolism, although the meaning of these changes for long-term disease risk is still being investigated.
- Thyroid and metabolic outcomes: Research has identified possible links with thyroid hormone disruption, obesity and diabetes, but findings are not equally consistent across all studies.
These associations should be interpreted carefully. An association means that two factors occur together more often than expected; it does not automatically prove that one caused the other. However, when results are observed across different populations and supported by laboratory evidence, the overall case for concern becomes stronger.
Immune function and childhood health
One of the more consistent findings concerns the immune system. Several studies have found that children with higher blood concentrations of certain PFAS produce fewer antibodies after vaccination. This does not necessarily mean that vaccines stop working, but the response may be less robust.
That distinction matters. Vaccination remains one of the most effective tools in public health, and PFAS exposure is not a reason to avoid recommended immunisations. Instead, the research raises concerns about whether persistent chemical exposure can subtly reduce immune protection at a population level.
Children may be particularly important in this discussion because they are still developing, have different patterns of food and water consumption relative to body weight, and may experience exposure during sensitive developmental periods. A Danish study of children, for example, reported an association between prenatal PFOA exposure and reduced antibody responses to childhood vaccinations. Similar observations have appeared in other cohorts, although results vary according to the PFAS measured and the timing of exposure.
Researchers are also examining whether PFAS influence the risk of infections, allergies or autoimmune conditions. The evidence is less settled in these areas, and more long-term studies are needed.
Cholesterol, metabolism and the cardiovascular question
Higher PFAS concentrations in blood have repeatedly been associated with elevated cholesterol. This finding has appeared in large population studies, including research using data from the US National Health and Nutrition Examination Survey. The association is most often reported for total cholesterol and LDL cholesterol, sometimes called “bad” cholesterol.
There is an important scientific complication: cholesterol itself may influence PFAS levels in the blood, and PFAS may also affect lipid metabolism. In other words, the relationship may be biologically complex rather than a simple one-way pathway. Even so, the consistency of the finding has made cholesterol one of the key health endpoints considered by regulators.
Whether PFAS directly increase the risk of heart attack or stroke is less clear. Cardiovascular disease develops through multiple interacting factors, including blood pressure, smoking, diet, physical activity and genetics. Current evidence supports concern about cardiovascular risk factors, but it does not allow researchers to calculate an individual’s future risk from a PFAS blood level alone.
Pregnancy, fertility and early development
Pregnancy is a period when exposure to environmental chemicals deserves particular attention. PFAS can cross the placenta, and some compounds have been detected in breast milk. Researchers have therefore studied prenatal exposure, birth outcomes and development during infancy and childhood.
Several studies have associated higher maternal PFAS levels with slightly lower birth weight. Other research has examined pre-eclampsia, gestational diabetes, reduced fertility and changes in the timing of puberty. The results are not identical across studies, partly because exposure levels, populations and measured PFAS differ.
A small change in average birth weight does not mean that every exposed pregnancy will have a poor outcome. It does, however, matter when exposure affects large populations. Public health experts pay attention to modest shifts in population averages because even a small change can increase the number of people at the extremes of risk.
People who are pregnant or planning a pregnancy should not panic. The practical focus should be on reducing avoidable exposure, following local drinking-water advice and discussing specific concerns with a qualified healthcare professional. Routine testing for PFAS is not currently recommended for everyone, and a blood result does not provide a simple treatment plan.
Cancer evidence: what is known and what remains uncertain
In 2023, the International Agency for Research on Cancer classified PFOA as carcinogenic to humans and PFOS as possibly carcinogenic to humans. These classifications describe the strength of evidence that a substance can cause cancer, not the level of risk faced by every person exposed to it.
For PFOA, the strongest human evidence relates to kidney and testicular cancer. Studies of highly exposed communities and workers have contributed significantly to this assessment. Some research has also explored associations with breast, prostate, pancreatic and other cancers, but findings are more variable.
PFOS has a more limited human evidence base. Its classification reflects evidence from human studies, animal experiments and biological mechanisms, but uncertainty remains about specific cancer sites and exposure levels. It is also important to remember that PFOA and PFOS are only two substances within a very large PFAS group. A lack of data on a replacement chemical should not be mistaken for proof of safety.
Why replacement PFAS are attracting attention
When manufacturers phase out well-known PFAS, they may replace them with shorter-chain substances or newer compounds. These alternatives can behave differently in the body and may leave the bloodstream more quickly. That sounds reassuring, but faster elimination does not automatically mean lower environmental risk.
Some replacement PFAS are highly mobile in water and can be difficult to remove through conventional treatment. Others have been studied far less extensively than PFOA or PFOS. Scientists call this the “regrettable substitution” problem: replacing a well-known hazardous chemical with a poorly studied alternative can shift, rather than solve, the risk.
This is one reason regulators increasingly consider PFAS as a broader chemical class, rather than assessing each compound in isolation. The approach recognises that persistence, mobility and limited toxicity data create challenges when regulation depends entirely on one chemical at a time.
Exposure does not equal disease
PFAS research can be alarming, particularly when headlines present an association as a certainty. A more accurate interpretation requires several questions:
- Which PFAS was measured?
- Was exposure assessed in drinking water, blood, food or another source?
- Was the study cross-sectional or did it follow participants over time?
- Did researchers account for age, smoking, income, diet and other possible confounding factors?
- Were the findings reproduced in different populations?
Long-term health research is difficult because people are exposed to mixtures, not isolated chemicals. PFAS can also be correlated with social, occupational or geographical factors that influence health. Blood levels may reflect exposure over many years, while a single health measurement captures only one moment.
These limitations do not dismiss the evidence. They explain why scientific agencies use terms such as “associated with” and why risk assessments are updated as new studies become available.
What can individuals do to reduce exposure?
The most effective action depends on the main source. If local authorities identify PFAS in drinking water, follow official guidance and check whether an approved treatment system is recommended. Activated carbon and reverse osmosis can reduce many PFAS when correctly selected, installed and maintained. Not every household filter is certified for PFAS removal, and a filter that removes chlorine or improves taste may not address these chemicals.
Useful steps may include:
- Checking local water-quality reports or contacting the water supplier.
- Using a filter certified by an independent body for the specific PFAS reduction claimed.
- Replacing cartridges according to the manufacturer’s schedule.
- Avoiding the use of contaminated water for drinking, cooking or preparing infant formula when official advice says not to use it.
- Reducing unnecessary contact with products marketed as stain-resistant or water-repellent when alternatives are available.
- Following food-safety advice rather than attempting unproven “detox” treatments.
Boiling water is not a reliable way to remove PFAS. In fact, evaporation can leave the chemicals behind while reducing the volume of water. The solution is targeted treatment and source control, not a hotter kettle.
Why monitoring and regulation matter
Individual choices cannot solve a contamination problem created by industrial use, firefighting foam or waste disposal. Long-term protection depends on monitoring, transparent reporting, effective pollution controls and the safe management of contaminated sites.
In the UK, drinking-water regulation is evolving as scientific understanding and analytical methods improve. Limits and guidance can differ between jurisdictions, partly because agencies use different assumptions about toxicity, combined exposure and acceptable risk. Readers should therefore consult current guidance from their local water supplier, the UK Drinking Water Inspectorate and public health authorities.
The central message from the evidence is neither that PFAS exposure is harmless nor that illness is inevitable. Some PFAS are linked to meaningful health effects, particularly after long-term exposure, while important uncertainties remain for many newer compounds. Reducing avoidable exposure, improving water treatment and preventing further contamination are sensible steps supported by the weight of current research.
PFAS may be persistent, but public policy does not have to be. Better testing, stronger controls and clearer information can reduce exposure over time—and give communities a more reliable way to protect health and the environment.